



FEATURED OPTIONS RADAR REPORT



Large Synthetic Bull Spread in Small Cap Diagnostics Company

Ticker/Price: QTRX (\$30.40)

Quanterix (QTRX) with a large trade on 1/31 as 3,446 March \$25 synthetic long positions opened at a \$5 debit with earnings expected in early March, the only notable open interest now in the name. QTRX shares traded above \$90 in early 2021 and have round-tripped the post-pandemic move and pulled back to a major long-term volume node of support before bouncing at the key \$26 level. Quanterix is a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on proprietary digital “Simoa” detection technology. The Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids. Simoa technology has been cited in more than 1,100 scientific publications in areas of high unmet medical need and research interest such as neurology, oncology, cardiology, infectious disease and inflammation. Simoa platforms have applications across the life science research, diagnostics and precision health screening markets. The addressable neurology, immunology and oncology life science research market is approximately \$1 billion per year. As QTRX expands its life science research focus in other areas of immunology, oncology and other therapeutic areas, coupled with growing adoption of decentralized clinical trials, the life science research addressable market is expected to expand to approximately \$7 billion. There is also the opportunity to access markets beyond research, such as diagnostics and precision health screening. QTRX now has a market ap of \$990M and trades 5.5X EV/Sales with revenues seen rising 19% in 2022 and 25%+ in the outer years though profitability is not expected within the next few years. QTRX guides above estimates at the JPM Conference on 1-13. Analysts have an average target of \$72 with short interest at 3.2% of the float.

Hawk Vision:



Hawk's Perspective: QTRX is a small cap I like for the opportunity ahead though tough to get behind companies lacking profitability in this environment, a buyout could be a potential outcome with shares now cheap on an EV/Sales basis. Picking spots in these types of names also requires adherence to strict/tight risk levels.

Confidence Ranking: \$\$